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There was no significant difference in late lumen loss, late loss index, or target sits binary 
rsstsnosis between vessels ~3.0 mm and 23.0 mm in diameter among the patients 
treated with ICR; however, there was a significantly greater edge effect in the smaller 
vessels. There was no correlation between vessel size and late lumen loss or late loss 
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0029-7 improved Outcome With Longer Radiation Sources: 
Final Results of the RENO Registry in 1898 Patients index, R=0.12 and R=-0.17, respectively. 
Conclusion: ICR effsctivek inhibits rsstenosis of the tamst sits in vssssls ~3.0 mm in 
diameter. Measures to mini&e edge effects (e.g., wide hdiation margins) are more crit- 
ical in smaller vessels. 
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0029-5 Fate of Nonfiow-Limiting Dissections After Treatment 
With Iridium-192 Therapy: Results From the GAMMA I 
and ii Trials 
&&&K&M Alexandra J. Lansky, Costantino Costantini-Ortiz. Maria Corral, Nishe 
Dave, Lubbe F. Dieter, Peter 8. Bergs,, Kartik Desai. Martin B. Leon, Cardiovascular 
Research Foundation, New York, Mayo Clinic, Rochester, Minnesota. 
Background: After conventional PTCA, residual dissections have been associated with 
an uneventful long-term clinical course. The clinical consequences of final non-flow-limit- 
ing dissections after PTCA in pta treated with adjunctive vascular brachytherapy (VBT) is 
not known. Methods: To gain insight into the clinical consequences of dissections after 
Iridium-l 92 therapy we reviewed the outcome of pts assigned to radiation in the GAMMA 
I and II trials (N-254). We compared the outcome of pts with a final dissection (N=7) to 
those without a dissection (N=247). Results: Lesion characteristics were similar at base- 
line with ACC/AHA class >B in 57% with vs 40.1% without dissection, p=O.446. Final 
angiographic results were similar in the 2 groups (Table). At follow-up, all the dissections 
healed without angiographic evidence of aneurysm, ectasia, or persistant dissection, 
however there was more flow compromise (FU TIMI< in 60% vs 13%, p&021) in pts 
with final dissections. Pts with dissections had a higher 30 day MACE rats (26.6% vs 
2.4%. p=O.O17) but no differences in 9 month revsscularization, despite more lumen 
compromise by angiography (table). 
Conclusion: After Iridium-192 VBT, a non-flow-limiting dissection remaining after final 
intervention will heal without angiographic evidence of luminal disruption at follow-up. 
However, pts with final dissections have higher 30 day MACE, therefore intra-procedural 
resolution of post-VBT dissections is recommended. 
No Dissection Dissection P Value 
Final Lesion %DS 
Final Stent % DS 
FU Lesion MLD, mm 
FU Lesion % DS 
Lesion Restenosis 
FU Total Occlusions 
Stent thrombosis % 
27.6% 26.1% 0.925 
13.0% 1.7% 0.096 
1.41 0.56 0.012 
47.7% 73.2% 0.029 
35.6% 60% 0.356 
12.1% 40% 0.123 
4.9% 0% 1.000 
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0029-6 Treating i&tent Restenosis in Long Coronary Lesions 
P. A. Morales, Richard R. Heusar, W. Laskey, R. Bonan, A. J. Lansky, J. J. Popma, St. 
Luke’s Medical Center/Phoenix Heart Center, Phoenix, Arizona, Brigham and Women’s 
Hospital, Boston, Massachusefts. 
Background: Following standard treatment of in-stent restenosis, clinical restenosis may 
be as high as 70% in long lesions. Results of the START (Stems and Radiation Therapy) 
trial indicate that the use of intracoronary beta radiation yields significant reductions in 
the incidence of recurrent in-stent restenosis as compared with placebo. 
Methods: In a subgroup of the START trial, results in patients (n=239) with coronary 
lesions >I5 mm in length were analyzed to assess treatment with a Z&mm beta radiation 
source train. Patients received an intracoronary catheter with QOStrontium/QOYttrium 
(n=l26) or placebo (n=lll). Clinical and angiographic parameters were evaluated at 6 
months. 
Results: Patient demographics and lesion characteristics as determined by angiography 
were similar between the two groups. The mean lesion lengths were comparable in the 
radiation (21.5 +/- 5.2 mm) and placebo groups (22.1 +/- 5.5 mm) (p=O.39). A total of 
14.1% of patients in the radiation group and 22.5% in the placebo group received new 
stsnts (p=O.O9). At an 6-month follow-up, radiation therapy yielded significant reductions 
in Major Adverse Cardiac Events (16.4% versus 29.7%, p=O.O14). Target Vessel Revas- 
cularization (14.6% versus 26.6%, p=O.O065), and Target Lesion Revascularization 
(11.7% versus 27.9%, p =O.OOlS). There were no cases of stsnt thrombosis, and angio- 
graphic data revealed significantly lower binary restenosis rates in the radiation group as 
compared to placebo (Stent Segment Binary Restenosis 17.9% versus 47.6%, p 
<O.OQOl; Analysis Segment Binary Restenosis 29% versus 52.7%. p=O.W07). 
Conclusions: These data suggest intracoronary beta radiation may prevent early rscur- 
rent restenosis in long lesions. Additional study is required to determine whether or not 
the reduction persists in mid- to long-ten follow-up. 
vSilber, Dietrich Baumgart. Antonio Colombo, Patrick Serruys, David Meerkin, 
Thomas Schiele, Rolf D&r, Klaus Kleinettz. We. Auch-Schwelck, William Wijns, Eric 
Eeckhout, Philip Urban, Dr. Miller Hospital, Munich, Germany. 
RENO is a European registry trial to assess the clinical event rate (MACE defined as 
death, Ml and/or NR) in patients with discrete lesions (de nova or rsstenotic) in single or 
multiple vessels (native and bypass grafts) treated with beta radiation (Novoste Beta- 
Cath). Between April 1999 and September 2000, 46 sites have enrolled 1096 patients. 
77.7% were treated for in-stent rsstenoais (ISR) and 17.7% for de-nova lesions in pre- 
dominantly (94.1%) native coronary arteries. Mean dose was 16.6+3.2 Gy with 16.5% 
30mm, 79.2 % 40mm and 4.3% 40 mm sources. The results are fisted in the table. 
Conclusions: These data surprisingly show an impmved outcome regarding angiogr. res- 
tenosis, total occlusion and MACE with longer radiation sources despite longer lesions. 
Radiation Source Length 30 mm 40 mm 60 mm 
Age (mean *SD) y: 62.3 * 9.9 62.1 k10.3 59.5 *9.2 
Diabetes 15.1 % 25.6 % 16.6 90 
ISR 70.1 % 79.2 % 75.4 % 
Lesion Length 15.5 * 9 mm 19.1 t 12 mm 30.9il4.7 mm 
Angiographic Restenosis (6 months) 27.7 % 24.1% 16.7% 
Total occlusion at f/up 7.9 % 5.3 % 3.2 % 
MACE (6 months) 20.4 % 16.6 % 12.2 % 
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Background: After vascular brachytherapy (VET) the impact of vessel size on long-term 
restanosis may diier from that expected after conventional PCI due to differences in dos- 
ing to the vessel wall. Methods: To understand the impact of vessel size on restenosis 
after VBT we reviewed the angiographic (QCA) results of 990 patients treated with 
Gamma VBT (N=370) and Beta VBT (N=265) versus placebo (N=355) after treatment of 
native coronary in-stem restenosis. Results: Regression analysis was used to construct 
probability models for treated segment restenosis (fig I) and stent edge restenosis (Fig 
2) based on vesasl size.By multivartate analysis, vessel size was an independent prsdlc- 
tar of treated segment restenosis (OR=O.551, p=O.O007) but not stem edge restenosis 
(~~0.537). Treated segment rsstsnosis was more likely with decreasing vessel size in all 
groups (less profound effect with Beta VBT). Stent edge restenosis appears more likely 
with decreasing vessel size after Bets VBT but with increasing vessel size after Gamma 
VBT. Conclusions: The probability of stent edge rsstenosis Increases in larger vessel 
sizes with Gamma radiation and in smaller vessels with Beta radiation suggesting differ- 
ing isotope dependent mechanisms. Further doss response analyses are necessary to 
better understand these counter-intuitive responses. 
